Why Easy Stem Cells Raise Hard Ethical Questions
By Brendan Foht,
The Public Discourse
| 02. 11. 2014
Late last month, Haruko Obokata and her colleagues at the RIKEN Center for Developmental Biology in Kobe, Japan
reported that they had discovered a surprising new technique for making stem cells. In a
pair of
articles published in the journal
Nature, they claimed that ordinary mouse cells could be made pluripotent (that is, having the ability to develop into any of the body’s tissue types) by exposing them to various forms of stress, such as acidic conditions.
The most obvious practical application of this new technique is that it could serve as a new source of pluripotent stem cells for regenerative medicine or for research. Initial results suggest that the technique is not only simpler than the genetic engineering techniques developed in 2006 to create induced pluripotent stem (iPS) cells, but also much more efficient at transforming cells to a pluripotent state.
There is still more work to be done before we know whether this procedure will work on the cells of adult humans. There are many differences between the stem cells of mice and humans, and the researchers...
Related Articles
By Abby Vesoulis, Mother Jones | 04.18.2026
Two years ago, we devoted an entire issue to the rise of the American oligarchy. Since then, our oligarchic system has become more entrenched and pervasive, revolving around a small crew of tech titans whose quest for wealth and...
By Sriparna Roy, Reuters | 04.23.2026
The U.S. Food and Drug Administration has approved Regeneron’s gene therapy for a rare genetic form of deafness, the company said on Thursday.
This approval, granted under the FDA’s new priority voucher program, marks the introduction of the first gene...
By Peter Ward, Slate | 03.30.2026
I’m in a cramped examination room at a clinic in Panama City. The lights are dim, and calming classical music plays from built-in speakers. A nurse has injected a dose of stem cells into Kenneth Scott through an IV in...
By Fyodor D. Urnov and Sadik H. Kassim, Nature | 04.21.2026
In February, the US Food and Drug Administration (FDA) proposed a radical rethink of how scientists, physicians and manufacturers develop personalized genetic therapies. The regulator’s suggested introduction of a ‘plausible mechanism pathway’ should increase incentives for drug companies to develop...